Spermon J R, Witjes J A, Kiemeney L A L M
Department of Urology, University Medical Centre, Nijmegen, Nijmegen, The Netherlands.
Urology. 2002 Nov;60(5):889-93. doi: 10.1016/s0090-4295(02)01886-1.
To compare the relative survival in men younger and older than 50 years with a testicular germ cell tumor.
Data on patients with testicular cancer diagnosed between 1973 and 1997 and registered by one of the nine population-based Surveillance, Epidemiology, and End Results (SEER) cancer registries in the United States were obtained from the National Cancer Institute public domain SEER*Stat 3.0 package. Survival rates adjusted for mortality owing to other causes (ie, relative survival) were calculated for men within each category of the American Joint Committee on Cancer staging system.
Patients who developed a germ cell tumor before the age of 50 years had better 10-year relative survival (90.8%, 95% confidence interval 90.6% to 91.0%) than those who developed one after the age of 50 years (84.0%, 95% confidence interval 81.9% to 86.1%). This difference remained after stratification by histologic type and stage, except for patients with localized seminomatous disease (97.9% versus 98.0% for men younger and older than 50 years, respectively). The largest difference in 10-year relative survival was found in men with metastasized disease: seminomatous disease, 89.7% versus 69.6%, and nonseminomatous disease, 76.9% versus 57.0%, for men younger and older than 50 years, respectively.
Lower stage and morphology-adjusted relative survival rate was observed among patients older than 50 years of age with testicular cancer. This difference was more evident in metastasized disease. Whether the worse prognosis in testicular cancer can be explained by a lower tolerance to chemotherapy and/or to suboptimal treatment in the elderly has to be established.
比较年龄小于50岁和大于50岁的睾丸生殖细胞肿瘤男性患者的相对生存率。
获取1973年至1997年间在美国9个基于人群的监测、流行病学和最终结果(SEER)癌症登记处之一登记的睾丸癌患者数据,这些数据来自美国国家癌症研究所公共领域的SEER*Stat 3.0软件包。针对美国癌症联合委员会分期系统的每个类别中的男性,计算调整了其他原因导致的死亡率后的生存率(即相对生存率)。
50岁之前发生生殖细胞肿瘤的患者10年相对生存率(90.8%,95%置信区间90.6%至91.0%)高于50岁之后发生生殖细胞肿瘤的患者(84.0%,95%置信区间81.9%至86.1%)。按组织学类型和分期分层后,这种差异仍然存在,但局限性精原细胞瘤患者除外(50岁以下和50岁以上男性分别为97.9%和98.0%)。10年相对生存率差异最大的是发生转移的疾病患者:50岁以下和50岁以上男性的精原细胞瘤分别为89.7%和69.6%,非精原细胞瘤分别为76.9%和57.0%。
50岁以上睾丸癌患者的分期和形态学调整后的相对生存率较低。这种差异在转移疾病中更为明显。睾丸癌预后较差是否可以用老年人对化疗的耐受性较低和/或治疗不理想来解释,还有待确定。